Functional characterization of 27 CYP3A4 protein variants to metabolize regorafenib in vitro

Ying-Hui Li1, Qian-Meng Lin1, Ni-Hong Pang1

  • 1Department of Pharmacology, School of Pharmacy, Wenzhou Medical University, Wenzhou, China.

Abstract

Insights

This study characterized 27 CYP3A4 variants’ impact on regorafenib metabolism. Four variants showed increased activity, one showed none, and others had decreased or similar activity compared to wild-type CYP3A4.1.

Area of Science:

  • Pharmacogenomics
  • Drug Metabolism
  • Enzyme Kinetics

Background:

  • Regorafenib, a tyrosine kinase inhibitor, is primarily metabolized by CYP3A4.
  • Genetic variations in CYP3A4 can significantly alter regorafenib metabolism.
  • Understanding these variations is crucial for personalized medicine and optimizing regorafenib therapy.

Purpose of the Study:

  • To investigate the in vitro catalytic characteristics of 27 novel CYP3A4 protein variants on the oxidative metabolism of regorafenib.
  • To determine how genetic polymorphisms in CYP3A4 affect regorafenib clearance.
  • To provide foundational data for clinical studies on regorafenib pharmacogenetics.

Main Methods:

  • Incubation of wild-type CYP3A4.1 and 27 variants with varying concentrations of regorafenib (0.5–20 μmol/L) for 30 minutes.
  • Detection and quantification of regorafenib-N-oxide, a key metabolite, using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS).
  • Determination of intrinsic clearance values for each CYP3A4 variant.

Main Results:

  • CYP3A4.20 exhibited no detectable enzyme activity.
  • Five variants (CYP3A4.5, .16, .19, .24, .29) showed clearance values comparable to wild-type CYP3A4.1.
  • Four variants (CYP3A4.14, .15, .28, .31) demonstrated significantly increased enzymatic activity, while the remaining variants displayed markedly decreased intrinsic clearance.

Conclusions:

  • This study provides the first comprehensive in vitro functional characterization of 27 CYP3A4 variants concerning regorafenib metabolism.
  • The identified variants exhibit diverse catalytic activities, impacting regorafenib clearance.
  • These findings may inform future clinical research and guide personalized regorafenib treatment strategies.

Related Concept Videos

Histone Variants at the Centromere02:30

Histone Variants at the Centromere

Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...
5.0K
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
3.7K
Structural Protein Function01:56

Structural Protein Function

Structural proteins are a category of proteins responsible for functions ranging from cell shape and movement to providing support to major structures such as bones, cartilage, hair, and muscles. This group includes proteins such as collagen, actin, myosin, and keratin.
Collagen, the most abundant protein in mammals, is found throughout the body. In connective tissue, such as skin, ligaments, and tendons, it provides tensile strength and elasticity.  In bones and teeth, it mineralizes to...
29.9K
Structural Protein Function01:56

Structural Protein Function

3.2K